MindMed development of new compounds is expected to play a role in blocking psychedelic drugs

According to foreign media reports, MindMed has developed a new compound with the help of Swiss researchers that is said to prevent the action of “Psychedelic Drugs” (LSD). It claims to have found the “switch” of LSD, which is helpful for clinicians to use safer symptomatic methods when treating patients. Before the statement was issued, MindMed revealed that it had signed an exclusive contract with liveti Lab for many years.

(From: MindMed)

it is reported that liechtelab is an LSD research laboratory led by Matthias Liechti of the University of Basel in Switzerland. JR Rahn, co-CEO of MindMed, said:

the innovative work of Liechti Lab has opened a data treasure house for LSD-related research. We are at the beginning of several major discoveries that are expected to further promote drug therapy for LSD.

MindMed said it had applied for a “neutralizer patented technology” aimed at shortening and blocking the influence time of LSD action during treatment.

At present, the specific compound composition is not clear, but the foreign media New Atlas has directly sent a consultation request to Matthias Liechti, hoping that he can inform what published studies have been made, and some insights into the current progress of the work.

Lietheti said the research team plans to explore the use of a variety of compounds to treat adverse effects of hallucinogens in order to enhance the safety of clinical use. However, the study is currently underway, so it is temporarily impossible to disclose specific details.

In an email reply to New Atlas, it explained that such treatments include those that usually include benzodiazepines or haloperidol.

As a compound that blocks the subjective and neurological effects of LSD, ketanserin has recently been used by many teams to study the mechanism of psychedelic substances.

Previously, ketosermulti was used as a clinical antihypertensive drug. It is said that it can destroy the action pathway of LSD by blocking the serotonin 2A receptor in the brain.

Liechti did not reveal whether the new compound could block the effect of LSD in a similar way, but it did show a glimmer of hope.

New drugs are designed to reduce the duration of action and the intensity of effects of large doses of LSD, such as in response to panic attacks or excessive intake. As for how fast the drug effect is, it still depends on the specific situation of the preparation being developed and tested.

MindMed added that the development of an effective LSD neutralizing compound is expected to greatly expand the safety of such therapies. Normally, the hallucinogenic effect of LSD lasts for 8 to 12 hours, so the clinical potential of such drugs is very limited.

The Company believes that if a compound can prevent the subjective effect of LSD, it is expected to be used in a wider range of clinical applications.

Currently, MindMed is conducting a two-stage experiment of treating high-dose LSD anxiety with lietheti Lab, and the micro-dose two-stage experiment for adult attention deficit hyperactivity disorder (ADHD) is about to begin.